Pablo Sainz-Cabezas
Santiago De Compostela, GA 15706, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Protamine-Based Nanotherapeutics for Gene Delivery to Glioblastoma Cells.
Journal: Molecular pharmaceutics
Published: April 02, 2025
Triazole-Derived Ruthenium(II) Complexes as Novel Candidates for Cancer Therapy.
Journal: ChemPlusChem
Published: December 19, 2024
Red blood cell-tumor cell interactions promote tumor cell progression.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 17, 2024
CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.
Journal: Molecular oncology
Published: July 10, 2024
Senotoxins target senescence via lipid binding specificity, ion imbalance and lipidome remodeling.
Journal: Nature aging
Published: December 21, 2023
Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.
Journal: Journal of experimental & clinical cancer research : CR
Published: October 15, 2023
Severe neurometabolic phenotype in npc1 -/- zebrafish with a C-terminal mutation.
Journal: Frontiers in molecular neuroscience
Published: October 24, 2022
In Vitro and In Vivo Biological Activity of Ruthenium 1,10-Phenanthroline-5,6-dione Arene Complexes.
In Vitro and In Vivo Biological Activity of Ruthenium 1,10-Phenanthroline-5,6-dione Arene Complexes.
Journal: International journal of molecular sciences
Published: September 13, 2022
The structural conformation of the tachykinin domain drives the anti-tumoural activity of an octopus peptide in melanoma BRAFV600E.
Journal: British journal of pharmacology
Published: October 13, 2021
N-Heterocyclic Carbene Iron Complexes as Anticancer Agents: In Vitro and In Vivo Biological Studies.
N-Heterocyclic Carbene Iron Complexes as Anticancer Agents: In Vitro and In Vivo Biological Studies.
Journal: Molecules (Basel, Switzerland)
Published: August 13, 2021
Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers.
Journal: Cell death and differentiation
Published: May 23, 2021
Last Updated: 09/26/2026